Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 2Central Nervous System Neoplasms 2Oligodendroglioma 1Gliosarcoma 1Cognition Disorders 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiosurgery 23Radiotherapy 20Temozolomide 17Lomustine 9Bevacizumab 8Surgical Procedures, Operative 7Procarbazine 6Vincristine 5Nivolumab 5Memantine 5Magnetic Resonance Spectroscopy 4Filgrastim 4Etoposide 4Cisplatin 4Carboplatin 4Specimen Handling 3Sodium Chloride 3Radiation 3Methylphenidate 3Mental Status and Dementia Tests 3Granulocyte Colony-Stimulating Factor 3Gefitinib 3Cyclophosphamide 3Corticotropin-Releasing Hormone 3Carmustine 3icotinib 2etoposide phosphate 2efaproxiral 2X-Rays 2Tranexamic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Brain Neoplasms × DNA Methylation × Clear all
NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡